Other Name: rhTPO
TPIAO is a recombinant human thrombopoietin (rhTPO) product used for the treatment of certain types of thrombocytopenia, a deficiency of platelets. Thrombopoietin (TPO) is a hemopoietic, or blood or blood cell-related, growth factor protein. TPO stimulates production of megakaryocytes, cells with a multilobed nucleus in the bone marrow and liver, which release mature platelets and raise the circulating platelet count in the blood. TPIAO may be used to stimulate platelet production in patients suffering from platelet deficiency associated with blood stem cell transplantation, cancer chemotherapy, late-state liver diseases, or for other pathological reasons.
EPIAO is an injectable recombinant human erythropoietin (rhEPO). Erythropoietin (EPO) is a natural growth factor produced in healthy kidneys that regulates production of red blood cells. EPIAO and other rhEPO products are used to stimulate the production of red blood cells in patients with anemia.
Patients with CKD, particularly late-stage patients undergoing dialysis treatments, often suffer from anemia because their kidneys are not able to produce sufficient amounts of EPO. Cancer patients receiving chemotherapy treatments may also suffer from anemia, which sometimes forces them to cease chemotherapy treatments. EPIAO and other rhEPO products can be used to treat such anemias, thereby improving the life quality for CKD and cancer patients and reducing the need for blood transfusions. In addition, EPIAO can be administered to surgery patients to prevent or ameliorate anemia caused by blood loss during surgeries.
IV Iron Sucrose, our iron sucrose injection product, is a complex of polynuclear iron (III)-hydroxide in a sucrose solution for intravenous administration. IV Iron Sucrose is indicated for the treatment of iron deficiency anemia. Compared to other forms of iron supplements such as oral iron supplements and iron dextran injections, iron sucrose injections have quicker onset, better efficacy, fewer side effects and more efficient iron absorption. As an intravenously administered drug, IV Iron Sucrose is especially suitable for patients who are unable to tolerate or effectively absorb orally administered iron supplements. IV Iron Sucrose can be prescribed in combination with EPIAO for late-stage CKD patients suffering from anemia or for patients with late-stage iron deficiency. IV Iron Sucrose is included in the National Medical Insurance Catalogue as a Category B drug.
Other Name: interferon alpha-2a
Intefen is a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases, including adult chronic hepatitis B, acute and chronic hepatitis C and genital warts. Interferon is a protein that is produced naturally in the body in trace amounts. When exposed to viruses, certain cells produce interferon, which is released into the bloodstream or intercellular fluid to induce healthy cells to produce enzymes and proteins that counter and combat the infection. The anti-cellular or immuno-regulatory functions of interferon enable interferon products to play a central role against certain tumor and autoimmune diseases. Interferon alpha has been manufactured by pharmaceutical companies for therapeutic use against hairy-cell leukemia, hepatitis C and hepatitis B, as well as for treatment of genital warts and some rare cancers of the blood and bone marrow.
Other Name: interleukin 2 (IL-2)
Inleusin is a recombinant human interleukin 2 (IL-2) product that is structurally and functionally similar to naturally produced IL-2, an immune regulator. IL-2 is a natural part of the human immune response to microbial infection. IL-2 promotes the proliferation and maturation of, among others, T-cells and natural killer cells, both of which are capable of destroying cancer cells directly. Inleusin is indicated for treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis.
Other Name: rhEPO
SEPO is an injectable rhEPO product manufactured and marketed by Sciprogen, which we acquired in December 2014.
Launched in 2001, SEPO has been approved by the CFDA for the treatment of anemia associated with CKD and the treatment of CIA. SEPO is included in the National Medical Insurance Catalogue as a Category B drug for the treatment of anemia associated with CKD and in eight provincial medical insurance catalogues (Fujian, Hainan, Heilongjiang, Hubei, Jilin, Liaoning, Shaanxi and Shanghai) for the treatment of CIA.
Other Name: LMWH-Ca
Sparin is an injectable low-molecular-weight heparin calcium (“LMWH-Ca”) product manufactured and marketed by Sciprogen, which we acquired in December 2014.
Heparin is the most widely used anticoagulant. LMWH-Ca is derived from depolymerization of standard heparin. Compared to standard heparin, LMWH-Ca has the advantages of lower side effects and more predictable anticoagulant response.
In addition to the products described above, we currently also sell metadoxine marketed under the trade name Gan Xin (甘忻), a drug used for the treatment of alcoholic liver disease.
In October 2014, we entered into an agreement with Zhejiang Wan Sheng Pharmaceutical Co. Ltd. (浙江萬晟藥業有限公司) to become the exclusive distributor of three anti-cancer drugs in the PRC. These drugs are docetaxel marketed under the trade name Si Qu Di (斯曲帝), anastrozole marketed under the trade name Rui Si Yi (瑞斯意) and azasetron marketed under the trade name Wan Wei (萬唯). We started selling these products in December 2014. These anti-cancer drugs have significantly expanded our product offerings in the oncology area.
Shi Ming Ke Li is a exclusive formula of TCM, manufactured and marketed by Wansheng Pharmaceutical,which we acquired in July,2015,indicated for the treatment of Type 2 diabetic retinopathy.It is first approved by CFDA as one of the national protected TCM in 2013.
YI LI XI is Rosiglitazone Hydrochloride Tablets,manufactured and marketed by Wansheng Pharmaceutical,which we acquired in July, 2015. YI LI XI is TZDS antidiabetic drug,by increasing insulin sensitivity and effectively control blood sugar, applying to other medications can't achieve the goal of blood glucose control in patients with type 2 diabetes
MAN DI is 5%Minoxidil tincture, the first OTC drug for baldness, manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015, used to treat male pattern baldness and alopecia areata. MAN DI is the first launched and first brand in domestic similar products.
LAIZI is Tacrolimus ointment, manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015,indicated for the treatment of local skin immune response for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis. LAI ZI is included in the National Medical Insurance Catalogue as a Category B drug.
DI SU is a BCG-PSN Injection, manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015.,DI SU is used to prevent and therapy chronic bronchitis, cold, asthma as new and efficient two-way immune regulator. Di Su is included in the National Essential Drug List 《國家基本藥物目錄》
LAI DUO FEI is Fexofenadine Hydrochloride Tablets, as the second generation H1-receptor antagonist, which can selectively block the H1 receptor and has good antihistamine effect, manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015. LAI DUO FEI is regarded as first-line drugs for a new kind of allergic rhinitis and antihistamines, with faster working time, longer duration of drug action
Liranaftate is a new type of the third generation of glucosinolates carbamate antifungal drugs,manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015, indicated for the treatment of tinea pedis,tinea corporis,tinea cruris.Compared to traditonal antifungal medication,Liranaftate show better antifungal therapy effect in clinical trials.
Amikacin is a topical solution of aminoglycoside antibiotics, manufactured and marketed by Wansheng Pharmaceutical, which we acquired in July, 2015,indicated for the treatment of serious trauma infection caused by sensitive bacteria. Amikacin show a high effect on various types of clinical drug resistance bacteria, can prevent bacterial infection, no stimulation to wound when spraying in local wound.